Clinical Trial News and Research

RSS

Adamis submits APC-100 IND to FDA for treatment of prostate cancer

Adamis Pharmaceuticals Corporation announced today that it has recently submitted to the FDA an Investigational New Drug application for APC-100 to treat prostate cancer.

9 Mar 2011

Study supports DNA mismatch repair test for bowel cancer

Bowel cancer patients whose tumors contain defects in specific DNA repair systems are much less likely to experience tumour recurrence post surgery, results from a major clinical study have demonstrated.

9 Mar 2011

GRACE model improves health and reduces Medicare costs in high risk seniors

The March 2011 issue of the journal Heath Affairs highlights an evidence-based model of geriatric care management developed, implemented and tested by researchers and clinicians from Indiana University, the Regenstrief Institute and Wishard Health Services.

9 Mar 2011

Novartis QAB149 receives FDA Pulmonary-Allergy Advisory Committee approval for COPD

An advisory committee recommended today that the Food and Drug Administration (FDA) approve QAB149 (indacaterol) 75 mcg in the US as a once-daily long-term maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

9 Mar 2011

New clinical trial to prevent aggressive type of breast cancer

In a first-of-its-kind clinical trial, physician-scientists at University Hospitals Case Medical Center are exploring a new method to potentially prevent recurrence of an early stage, aggressive type of breast cancer.

9 Mar 2011

Study finds AFFIRM assay may accurately detect Trichamonos vaginalis

A study from the microbiology lab at Rhode Island Hospital has found that a new test may be more accurate in identifying a common sexually transmitted infection, Trichamonos vaginalis.

8 Mar 2011

Plexxikon commences PLX3397 Phase 2 trial in patients with Hodgkin lymphoma

Plexxikon today announced that it has treated the first patient in a Phase 2 clinical trial in Hodgkin lymphoma with PLX3397. This novel agent is an oral, selective inhibitor that down-modulates two key cell types that are thought to mediate the progression of Hodgkin lymphoma tumors — macrophages and mast cells.

8 Mar 2011

Patrys succeeds in obtaining commercial yields for its anti-cancer antibody therapeutic

Patrys Limited (ASX: PAB), which is developing a new class of antibody molecules for the treatment of cancer, is pleased to announce success in obtaining commercial production yields for natural human antibody PAT-SC1, facilitating the advancement of this promising product toward a second human clinical trial for the treatment of cancer.

8 Mar 2011

Vertos reports long-term safety and efficacy of mild in patients with LSS

Medical device company Vertos Medical Inc. has announced the release of clinical study data demonstrating the long-term safety and efficacy of mild as well as its superior durability over epidural steroid injections for treating lumbar spinal stenosis.

8 Mar 2011

Neoprobe reports positive feedback from FDA for RIGScan development

Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, today announced that it has completed a successful pre-IND meeting with the U.S. Food and Drug Administration on the development of RIGScan CR, the Company's proprietary radiopharmaceutical for the detection of colorectal cancer tumors.

8 Mar 2011

GTHP provides update on FDA PMA review for LightTouch non-invasive cervical cancer test

Guided Therapeutics, Inc., today provided an update on the U.S. Food and Drug Administration review process for its premarket approval application for the LightTouch non-invasive test for the early detection of cervical pre-cancer.

8 Mar 2011

BrainScope announces launch of Ahead EU-100 to help in head injury assessment

BrainScope Company, Inc. announced today that it is preparing for the introduction of the Ahead™ EU-100, a product in development to aid in the assessment of head injury, in the United Kingdom.

8 Mar 2011

Mississippi researchers work on drug discovey for poison ivy skin rash

Each year nearly 50 million Americans develop an annoying skin rash after coming in contact with poison ivy. But University of Mississippi researchers are working on a pharmaceutical product to rein in the allergic reaction in people already sensitive to the plants and prevent it altogether in those who aren't.

8 Mar 2011

URMC research confirms possible use of mifepristone for painful fibroids

Research continues to show that the controversial abortion drug mifepristone might have another use, as a therapeutic option besides hysterectomy for women who suffer from severe symptoms associated with uterine fibroids.

8 Mar 2011

First western U.S. hand transplant surgery performed at UCLA Medical Center

Surgeons at Ronald Reagan UCLA Medical Center performed the first hand transplant in the western United States in an operation that began one minute before midnight on Friday, March 4, and was completed 14-and-a-half hours later, on Saturday, March 5.

8 Mar 2011

New clinical trial to assess antiretroviral treatment in HIV-infected individuals based on CD4 counts

A major new clinical trial seeks to determine whether HIV-infected asymptomatic individuals have less risk of developing AIDS or other serious illness if they begin taking antiretrovirals sooner rather than later, based on their level of CD4+ T-cells.

8 Mar 2011

Top-line results from Repligen RG2417 Phase 2b trial results in patients with bipolar depression

Repligen Corporation announced today results of a Phase 2b clinical trial of RG2417, an oral formulation of uridine, in patients with bipolar depression.

8 Mar 2011

New discovery can provide insight into lung cancer

A discovery at University of Colorado Cancer Center shows testing lung cancer on a molecular level can produce new insights into this deadly disease.

8 Mar 2011

NanoLogix announces MRSA testing preliminary results, new Science Advisory Board members at UTHSC

NanoLogix, a biotechnology innovator in the rapid detection and identification of live-cell microorganisms, announces preliminary results of MRSA testing at the University of Texas Health Science Center - Houston. Dr. Jonathan Faro, M.D., Ph.D. has found NanoLogix technology is able to deliver results for MRSA in 6 hours, as opposed to conventional culture-based testing wait times of 24 to 48 hours.

7 Mar 2011

Inovio initiates VGX-3100 Phase II trial in patients with cervical cancer

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it is initiating a Phase II clinical trial for its VGX-3100 DNA vaccine for cervical dysplasia and cancer caused by human papillomavirus.

7 Mar 2011